Cambium Bio (ASX:CMB) EPS without NRI: A$-0.19 (TTM As of Dec. 2025)


ASX:CMB Cambium Bio Ltd ASX:CMB
35 GF Score
Price A$0.43
! 4 Warning Signs
View Full Analysis

What is Cambium Bio EPS without NRI?

Cambium Bio ASX:CMB +2.38% 35 EPS without NRI is A$-0.19 as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review. Among 1,172 Biotechnology companies, Cambium Bio ranks better than 82.59% on this metric.

Cambium Bio's earnings per share without non-recurring items for the six months ended in Dec. 2025 was A$-0.07. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.19.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cambium Bio's EPS without NRI or its related term are showing as below:

ASX:CMB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -40.1   Med: 8.2   Max: 46.9
Current: 46.9

ASX:CMB's 3-Year EPS without NRI Growth Rate is ranked better than
82.59% of 1172 companies
in the Biotechnology industry
Industry Median: 16.8 vs ASX:CMB: 46.90

Cambium Bio's EPS (Diluted) for the six months ended in Dec. 2025 was A$-0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.19.

Cambium Bio's EPS (Basic) for the six months ended in Dec. 2025 was A$-0.07. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.19.


Cambium Bio  (ASX:CMB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cambium Bio EPS without NRI Related Terms


Cambium Bio EPS without NRI Historical Data

* Premium members only.

The historical data trend for Cambium Bio's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio EPS without NRI Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 -1.40 -1.10 -0.54 -0.21

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.10 -0.14 -0.12 -0.07

ASX:CMB vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Cambium Bio's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cambium Bio PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cambium Bio's PE Ratio without NRI falls into.


ASX:CMB
35GF Score
Cambium Bio Ltd ASX:CMB
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of A$-0.19 mean?
Cambium Bio (ASX:CMB) has a EPS without NRI of A$-0.19 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cambium Bio and its competitors. According to the industry distribution chart, Cambium Bio ranks #204 out of 1172 companies in the Biotechnology industry, placing it in the top 17.4%.
Is Cambium Bio's EPS without NRI too high?
Cambium Bio's current EPS without NRI is A$-0.19. Based on the distribution chart, Cambium Bio ranks #204 out of 1172 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #204 out of 1172 companies for EPS without NRI. This places Cambium Bio in the top 17% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cambium Bio and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambium Bio's current EPS without NRI is A$-0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current EPS without NRI of A$-0.19. The current EPS without NRI is A$-0.19. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current EPS without NRI is A$-0.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score

Get the complete analysis for ASX:CMB

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.43
Price